Objective: To investigate the contribution of serum levels of testosterone (TS) and sex hormone binding globulin (SHBG) in association with body mass index (BMI) as a surrogate marker of obesity, to the predictive capability of tumor size (T), lymph node (N) and estrogen receptor (ER) status and proliferative activity (TLI). Methods: We investigated 120 women with primary breast cancer and median follow-up of 138 months. Serum levels of TS and SHBG and patient's BMI were evaluated before surgery. The contribution of TS, SHBG, their ratio (TS/SHBG) and BMI to the predictive capability of tumor-specific biomarkers was investigated by Harrell's c statistic. Results: TS alone did not affect prognosis, whereas SHBG was protective in postmenopausal patients, in which BMI was associated with a progressive increase in the relapse-specific hazard ratio (HR). When in combination, TS, SHBG and BMI, affected prognosis in different ways depending on menopausal status. The best predictive capability (c = 0.78) was observed in postmenopausal patients when at the basic model (N + TLI) were added TS, BMI, TS * BMI interaction, with or without SHBG. In premenopause subgroup, the best predictive capability (c = 0.67) was provided by the basic model (N + TLI) plus TS and SHBG or their ratio, BMI and TS * BMI or TS/SHBG * BMI interaction. Conclusions: Patient-associated features such as BMI and serum levels of TS and SHBG can improve the predictive capability of consolidate tumor-specific biomarkers in both pre-and postmenopause, thus providing a relevant contribution to the decision-making process.
Introduction
In association with TNM staging, some specific features of breast cancer including hormone dependence in terms of estrogen (ER) and progesterone receptor (PR) status, proliferative activity (Ki67) and HER2 overexpression are routinely evaluated both in advanced and operable patients to assess prognosis and establish the best medical therapy to be applied. On the contrary, little consideration is generally given to the features closely associated with the patient, with the exception of age and menopausal status. In particular, no decisionmaking relevance has so far been recognized to the hormonal milieu of the patient and to the presence of metabolic disorders, particularly those associated with obesity, which may alter and negatively affect the response to therapy. This, in spite of accumulating evidence that the increase in serum levels of some sex hormones (mainly estrogens and androgens) is not only positively associated with high risk of developing breast cancer (1,2) but also with disease recurrence and unfavorable outcome (3) . Already in early 1970s, pioneering studies by Grattarola et al. (4, 5) highlighted the association between overproduction of testosterone (the most active androgen) and onset and progression of breast cancer. Subsequent studies by Secreto et al. (6) (7) (8) showed that the rate of recurrence in breast cancer patients with high levels of serum and urinary testosterone was significantly higher than that of patients with low levels of circulating hormone or normal excretion levels in both pre-and postmenopausal women.
The most accepted biological explanation of the adverse effect of testosterone on tumor onset and cancer progression in untreated patient is based on the activity of the aromatase enzyme that converts testosterone to estradiol, which in turn stimulates the proliferation of tumor cells expressing the estrogen receptor (ER). As the main peripheral source of aromatase is the white adipose tissue, the abnormal accumulation of fat (obesity) is thought to play a key role in the proliferation of ER-positive tumor cells through a continuous supply of estrogens. Consistent with this hypothesis, epidemiologic and clinical studies have clearly indicated that the occurrence and progression of breast cancer is associated with increased body fat. In particular, it has been shown that in postmenopausal women, accumulation of fat in the abdomen (visceral obesity) due to the redistribution of adipose tissue following the decline in ovarian function (9) , is associated with increased risk of distant recurrences (10) and bad prognosis (11) .
The bioavailability of circulating testosterone (TS) is primarily controlled by the sex hormone binding globulin (SHBG) which sequesters free testosterone and prevents its conversion to estradiol by tissue aromatase. Clinical evidence indicates that high levels of SHBG are significantly associated with a lower risk of breast cancer while low levels of SHBG and high levels of free testosterone are associated with a high risk (12) .
Aim of the study was to investigate the contribution of TS and SHBG, their ratio (TS/SHBG) also known as free androgen index, and body mass index (BMI), to the predictive capability of some tumor-associated biomarkers commonly used to evaluate prognosis and establish the suitable therapy. For this purpose, we investigated a cases series of patients with operable breast cancer and median follow-up of 138 months.
Patients and methods
The cases series includes 120 women with a primary breast cancer surgically treated at the Breast Surgery Unit of the Fondazione IRCSS Istituto Nazionale Tumori (INT) of Milan between March 1983 to March 1986. Inclusion criteria were: no ovariectomy, hormone treatments suspended for at least 3 months, and no congenital endocrine disorder.
At the time of initial diagnosis, patient's BMI was recorded. Women with BMI < 25 kg/m 2 were classified as lean, those with BMI ranging from 25 to 29.9 kg/m 2 as overweight and those with BMI ≥ 30 kg/m 2 as obese.
Before surgery, patients provided a fasting blood sample (premenopausal women on the 18th−22nd day of their menstrual cycle), which was processed to obtain serum, subdivided into aliquots and stored at −80°C until measurement of testosterone and SHBG levels by radioimmunoassay (RIA). Commercial kits purchased from Biomerieux (Charbonnier les Bains, France) for testosterone and from Farmos Group Ltd. (Oulunsalo, Finland) for SHBG were used according to the manufacturer's instructions. As previously described (13) , before RIA ether extraction and partition chromatography using Celite columns were performed to elute testosterone from serum.
Immediately after surgery, tumor specimens were in part frozen in liquid nitrogen and stored at −80°C for the measurement of hormonereceptors content, and in part incubated with 3 H-thymidine for the evaluation of thymidine-labeling index (TLI). Concentration of estrogen (ER) and progesterone (PR) receptor was biochemically measured by ligand binding assay and multiple-point Scatchard analysis, as previously described (14) . TLI was expressed as the percentage of 3 Hthymidine labeled cells respect to total number of tumor cells and the value of 3% was used to discriminate between slowly and highly proliferating tumors (15) . A cutoff value of 10 fmol/mg of cytosol proteins was used to quantify steroid receptors.
According to the therapeutic protocol in use at the time at INT, regardless of hormone receptor status, node-positive patients were scheduled to receive the CMF (cyclophosphamide, methotrexate, 5-fluorouracil) regimen (16) . Alternatively, if patient refused chemotherapy, 20 mg of tamoxifen daily for 1 year were prescribed. Nodenegative patients received no adjuvant treatment.
Patients were regularly followed up until March 2008 by surgeon senologist: every 4 months for the first 3 years after surgery, every 6 months for the following 2 years and once a year thereafter by bone scan, abdominal ultrasonography, CT scan, and biochemical blood testing. Follow-up information including date of last control, date and site of breast cancer recurrence, presence of a primary non-breast cancer, date and cause of death were recorded.
The median follow-up was 138 months (range, 3-299). The events used as end points in the determination of disease-free survival (DFS) included first local recurrence of disease, axillary and distant metastases, contralateral breast cancer and occurrence of a second primary tumor (5, 47, 3 and 8 cases, respectively). According to menopausal status, relapse occurred in 37 premenopausal and 26 postmenopausal women. Patients with synchronous bilateral carcinomas or treated for previous malignant tumors were excluded from the analysis. Of the 120 patients included in the study, 46 died: 38 after a previous relapse of breast cancer, and eight without experiencing a breast cancer relapse before. These eight patients were considered as censored in the analysis on DFS.
The study was approved by the INT Scientific and Ethical Committee and written informed consent was obtained from all patients.
Statistical analysis
Frequencies and percentages were used to describe selected characteristics of the study population and Fisher exact test was adopted for the association between variables. For continuous variables, Wilcoxon-Mann-Whitney test was used to compare median values in the different classes. The correlation between continuous variables was investigated by Spearman's correlation coefficient.
The joint effect of prognostic variable on DFS was investigated by a multivariable Cox regression model using ER, TLI, TS, SHBG, TS/SHBG as continuous variables. Tumor size (T) was classified according to pT categories (T1, T2, T3); axillary lymph nodes status (N) was classified as negative (N-) and positive (N+); BMI value was classified according to BMI categories (<25, 25-29.9, ≥30). The impact of adding each prognostic variable or their interaction was tested by likelihood ratio test. P value below 0.05 was considered statistically significant.
The predictive capability of the models was investigated by Harrell's c statistic (17) , which can assume values ranging between 0.5 and 1.00. Since the value of c index obtained from data used for model estimating provides an optimistic measure of predictive ability, values of c index corrected for the optimism by bootstrap method using 500 samples were also reported (18) . If the model has no predictive ability (i.e. the variables are not useful discriminators for the outcome), the c index is expected to be 0.5, whereas it tends to be 1.00 in the case of a high prognostic ability. The contribution of each variable to the predictive capability of the model was investigated by computing the c index on the model excluding the variable itself. In order to aid a clinical interpretation, we suggest that a value ranging between 0.6 and 0.7 be considered as a weak predictor, a value ranging between 0.71 and 0.8 a satisfactory predictor, and a value greater than 0.8 a good predictor. As the results of a multiple regression model could be influenced by the ratio of the number of events to the number of terms considered, to avoid model over-parameterization, the contribution of BMI, TS, SHBG and TS/SHBG was challenged in three distinct basic models including respectively N and T (N + T), N and ER (N + ER), or N and TLI (N + TLI).
The improvement in the discriminative ability of TS, BMI and their interaction term to the basic model was evaluated by Net Reclassification Improvement (NRI) for survival analysis. Results were reported as ½ NRI, being interpreted as an average improvement in classifying patients as alive or deceased at specific time point (19) . Confidence interval and P value of ½ NRI were obtained by bootstrap method, using 500 samples.
In Fig. 1 the plot of relapse-specific hazard ratio (HR) for TS, SHBG and TS/SHBG were drawn in the two groups of pre and postmenopausal women. The first quartile of the variable of interest was taken as reference value in each plot. Estimated HRs with respect to the first quartile with pertinent 95% confidence intervals were provided by the univariate Cox model (no adjustment for other variables is provided).
In Fig. 2 , the plot of TS or TS/SHBG relapse-specific HR in the different BMI categories was drawn. The first quartile of circulating TS or TS/THBG value in the specific menopausal group was taken as reference value. Estimated HRs were provided by the Cox model in the different BMI categories with pertinent 95% confidence intervals.
All statistical analyses were carried out using R statistical software v.3.3.3 with rms version 5.1-0 and survIDINRI, version 1.1-1, packages. Table 1 summarizes tumor and patient characteristics according to menopausal status and potential confounders (type of surgery, tumor histology and size, axillary node status, ER and PR status, and TLI) whereas Table 2 provides a descriptive statistics of patient's age TS, SHBG, TS/SHBG ratio and BMI. Of the 120 patients entered the study, 62% were premenopausal women.
Results
Overall, 74 (61%) patients were lean, 32 (27%) were overweight and 14 (12%) were obese. In particular, while obese patients were equally distributed in pre-and postmenopause (11% and 13% respectively), the percentage of lean women was higher in pre-than in postmenopause (69% vs. 49%). Conversely, postmenopausal patients were more frequently overweight than those in premenopause (38% vs. 20%) according to epidemiological evidence of a postmenopausal weight gain due to redistribution of adipose tissue following the decrease in ovarian steroids.
Relationships among circulating levels of TS, SHBG and BMI according to menopausal status
As regards circulating levels of TS and SHBG, a clear decrease in serum concentration of both molecules was observed in postmenopausal patients (Fig. S1 ). TS median value decreased from 0.33 ng/ ml in premenopause to 0.20 ng/ml in postmenopause (P = 0.0004); SHBG median value decreased from 43.9 ng/ml in premenopause to 33.9 ng/ml in postmenopause, although not in a statistically significant manner (P = 0.1183). Consequently, also their ratio decreased in postmenopausal patients.
When serum levels of TS and SHBG were analyzed according to BMI (Fig. S2) , we observed that in premenopause subgroup circulating level of TS was rather variable, with lean and obese patients having the same TS median value (0.38 ng/ml). Conversely, postmenopausal patients showed a slight but regular increase in TS median from lean to obese women in agreement with previous findings in healthy women (20) .
In both menopausal subgroups the increase of BMI was associated with a decreased level of SHBG. However, while in premenopause subgroup the decrease was progressive from lean (48.5 ng/ml) to overweight (37.2 ng/ml) and obese women (23.4 ng/ml), in postmenopause subgroup a clear-cut decrease was observed between lean (50.8 ng/ml) and overweight/obese patients (respectively, 28.4 and 29.6 ng/ml). Consequently, the TS/SHBG ratio, which accounts for the bioavailability of free TS, showed a marked increase in obese premenopausal patients and a moderate but evident increase in overweight and obese postmenopausal women (Fig. S2) .
Effect of TS, SHBG or TS/SHBG ratio on patient outcome
As regards the impact on patient outcome of TS, SHBG or TS/SHBG, results provided interesting information. When considered alone, TS showed a different impact on patient outcome according to the menopausal status. While in postmenopausal women increasing level of circulating testosterone had no significant effect on the hazard ratio for 0.1 unit increase in TS level (HR = 1.084, 95% CI: 0.776-1.515, P = 0.635), in premenopausal patients it showed a bell-shape profile having low or high TS levels a protective effect, and intermediate values being positively associated with an increased HR (Fig. 1) .
Even SHBG alone showed a different behavior according to the menopausal status. While in the premenopause subgroup increasing levels of SHBG had no significant effect on patient prognosis (HR for 10 unit increase of SHBG is 0.947, 95% CI: 0.767−1.169, P = 0.611), in the postmenopause subgroup increasing levels of SHBG were associated with a significant progressive decrease in the HR (HR for 10 unit increase of SHBG is 0.565, 95% CI: 0.385-0.830, P = 0.004). The protective role played by the increasing concentration of SHBG was more evident when we considered the impact on patient outcome of the TS/SHBG ratio. As shown in Fig. 1, an increased TS/SHBG ratio, which corresponds to an increased bioavailability of free circulating testosterone, was significantly associated with a sharp increase of the HR (P = 0.001).
When we evaluated the possible time varying effect of the covariates of interest over all follow-up time, by including in the models an interaction term between the covariate and time, no significant effect were observed.
Effect of BMI on patient outcome
Regardless menopausal status, BMI proved to be strongly associated with an increased frequency of relapse: while 35 out 73 (48%) lean patients experienced disease recurrence, more than 60% of overweight (19/31, 61%) and obese patients (9/14, 64%) had a relapse. The increase in frequency of relapse was associated with an increased relapse-specific hazard. Indeed, respect to lean women, the HR of overweight patients was 1.65 (95% CI: 0.94-2.91, P = 0.082) whereas the HR of obese patients respect to overweight women was 1.94 (95% CI: 0.92-4.06, P = 0.080). However, while in premenopause, the HR of overweight or obese patients respect to lean women were similar (1.268, 95% CI: 0.57-2.81, and 1.22, 95% CI 0.42-3.50, respectively), in postmenopausal patients a net and progressive increase of HR was observed. Respect to lean women, the HR of overweight patients was 1.87 (95% 
Effect of TS, SHBG or TS/SHBG ratio in combination with BMI on patient outcome
The interactions between variables were investigated in a bivariate fashion by including in the Cox model the main effects for the two considered variables and their first-order interaction terms. Table 3 and Fig. 2 show the interactions statistically significant and therefore included in the multivariate analysis. Noteworthy, in postmenopausal lean women the risk of relapse increased with increasing levels of testosterone, till the value of 0.2 ng/ml, and then declined, whereas in overweight women the risk of relapse constantly increased with increasing levels of testosterone, and in obese women the risk of relapse seemed to decrease at increasing levels of testosterone, suggesting that high circulating testosterone levels were not per se a risk factor in this BMI category. A different interaction was observed in premenopausal women where the risk of relapse increased at increasing levels of testosterone and thereafter decreased, with a variable maximum risk according to BMI class.
When we considered the impact of TS/SHBG ratio, we found that in premenopausal women, a slight decrease of HR with increasing TS/SHBG values was observed between lean and overweight patients whereas obese patients showed a fast increase of HR at increasing values of TS/SHBG. On the contrary, in postmenopausal women a different trend was observed. In lean and obese patients, the risk of relapse increased at increasing values of TS/SHBG up to 0.005 and 0.008 respectively, and then decreased whereas in overweight patients the risk of relapse progressively increased at increasing values of TS/SHBG.
Predictive capability of survival models
As shown in Table 4 , the predictive capability of the three basic models (N + T, N + ER, N + TLI) was very low in both menopausal subgroups. None of them reached the cutoff value needed to be ranked at least as a weak predictor (c = 0.60). In the case of N + T and N + ER basic models, none of the tested combinations (TS, SHBG, TS/SHBG and BMI alone or in combination, with or without interaction) significantly improved predictive capability. The best c values were those associated with the model including N, T and TS/ SHBG (c = 0.65) or the model including N, ER and SHBG (c = 0.62), but only in the postmenopause subgroup. Conversely, a substantial increase in the predictive capability was observed when at basic N + TLI model were added TS, BMI, SHBG, TS/SHBG and the interaction between TS and BMI (TS * BMI). Improvement in the predictive capability was evident in both menopausal subgroups, In premenopause subgroup, in fact, the best predictive capability (c = 0.67) was provided by the model that includes N, TLI, BMI, TS and SHBG or their ratio, and the interaction TS * BMI or TS/SHBG * BMI. However, when evaluated by NRI, the addition to the basic model (N + TLI) of BMI, TS and SHBG or their ratio, and TS * BMI or TS/SHBG * BMI interaction, showed to improve the capability to predict the probability of relapse at 15 years in a statistically significant manner (respectively, NRI = 0.659, 95% CI: 0.293-0.869, P < 0.001 for TS and SHBG, and NRI = 0.6, 95% CI: 0.195-0.854, P = 0.008 when TS and SHBG were replaced by their ratio).
Discussion
In the present study, we examined the contribution provided by some patient-associated features to the predictive capability of some consolidate tumor-associated biomarkers such as tumor size, axillary lymph nodes status, ER and TLI. Specifically, in addition to patient's menopausal status, we considered the circulating levels of TS and SHBG, which provide information about the bioavailability of testosterone, and BMI as a surrogate marker of patient's obesity status. Findings confirmed that TS, SHBG and BMI are associated to prognosis in different ways, depending on patient's menopausal status and their combination. Moreover, for the first time in our knowledge, results indicated that jointly TS, SHBG and BMI are able to improve the predictive capability of two important outcome prognosticators such as axillary node status and the proliferative activity of the tumor. Obesity is a growing social problem because of its close association with a wide range of pathological conditions including metabolic syndrome, cardiovascular diseases, and cancer onset and progression. In particular, epidemiological studies have clearly indicated that in breast cancer, already a limited increase in body fat (generally referred to as overweight) can have serious consequence both in pre-and postmenopausal women due to the capability of adipose tissue to convert androgens into estrogens (21, 22) . It is recognized, in fact, that testosterone-to-estradiol conversion by tissue aromatase can affect breast cancer progression by stimulating tumor cells proliferation via estrogen receptor (2, 3) .
For these reasons, since early 1970s the evaluation of circulating level of testosterone has been proposed as a patient-associated marker to be added to the consolidated tumor-associated biomarkers to improve prognosis and the decision-making process for the choice of the best adjuvant treatment.
Present results indicated that the information provided by the measurement of circulating levels of testosterone and SHBG in association with BMI, as expression of the obesity/overweight status of the patient, significantly improved the predictive capability of some consolidate tumor markers, routinely used to assess patient prognosis. In addition, findings provided insights on the complex interrelationship between adipose tissue and androgens metabolism. In fact, they clearly indicated that a BMI value >30 associated with high levels of free testosterone, as indicated by a high TS/SHBG ratio, are more frequently related with a short disease-free survival. It is well known that androgens and obesity are closely interrelated and that testosterone favors the accumulation of abdominal fat especially, but not exclusively, in postmenopausal women (23) . In turn, adipose tissue contributes to poor prognosis with an increased production of adipocyte-secreted factors, including insulin and insulin-like growth factors that accelerate tumor cell proliferation and impair treatment response. As this 'dangerous relationship' between body fat and androgens-to-estrogens conversion has proved to affect breast cancer progression independently of menopausal status-the only patient-associated feature currently considered for the disease management-the evaluation of circulating levels of testosterone and SHBG in association to BMI assessment, and their different relationship according to patient's menopausal status become clinically relevant to refine the predictive capability of classical tumor-associated markers.
In particular, our results support the clinical relevance of the evaluation of circulating levels of SHBG, due to the pivotal role that this protein exerts on the control of testosterone bioavailability. Serum concentration of SHBG, which is primarily produced by the liver, is the result of a balanced effect of stimulatory factors (mainly estrogens) and inhibitory factors such as androgens, insulin, excess body fat and the pattern of body fat distribution. Disruption of this regulatory mechanism due to the physiological reduction of estradiol level in postmenopausal women or insulin resistance-the major causative factor in development of metabolic syndrome-can result in a marked reduction of SHBG concentration. Consequence of such a reduction is the increase of SHBG-unbound testosterone which, in turn, exerts a double synergistic negative effect and activates a dangerous vicious circle. Free testosterone, in fact, inhibits SHBG synthesis thus further increasing testosterone bioavailability, and favors the accumulation of body fat (especially abdominal fat) where testosterone is converted into estrogen by the aromatase.
Certainly, our cases series suffers from two potential limitations: the small number of cases and the fact that, according to the therapeutic protocol in use at the time, regardless of hormone receptor status node-positive patients were scheduled to receive chemotherapy whereas node-negative patients did not receive any adjuvant treatment. Only when patients refused chemotherapy, ER-positive cases received adjuvant tamoxifen for 1 year. On the other hand, the homogeneity in the adjuvant treatment prescribed, though obsolete respect to currently used adjuvant regimen, and the long follow-up gave us the opportunity to explore the long-term effects of the association among circulating testosterone, SHBG and BMI on patient outcome, thus providing additional information about the long-term impact of some relapse risk factors not yet considered as potential therapeutic targets. Measuring these features, in addition to classic tumor markers, would allow to identify women with high risk of relapse on the basis of their endocrine-metabolic profile, and for which clinical surveillance should be more stringent. Although obtained with a small cases series, results clearly suggest that, in both in pre-and postmenopause, the assessment of circulating levels of testosterone and SHBG in association with BMI can greatly contribute to refining the predictive capability of two consolidate and independent tumor-specific outcome prognosticators (axillary lymph node status and TLI), which express the proliferative and metastatic potential of the tumor, providing useful information on the close relationship among androgen bioavailability, body fat accumulation and tumor progression, and allowing the identification of those patients who need a more tailored therapy with anti-androgens.
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